Author

W. S. Teo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

A. McFarland· 2 shared A. S. Cazet· 2 shared A. Swarbrick· 2 shared B. A. Varghese· 2 shared D. L. Roden· 2 shared H. Holliday· 2 shared N. Karthikeyan· 2 shared R. Murali· 2 shared

Activity by Year

2019-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. McFarland

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Id proteins promote a cancer stem cell phenotype in triple negative breast cancer via negative regulation of Robo1

W. S. Teo, H. Holliday, N. Karthikeyan, A. S. Cazet, D. L. Roden, K. Harvey, C. V. Konrad, R. Murali, B. A. Varghese, A. P. T., C.-L. Chan, A. McFarland, S. Junankar, S. Ye, J. Yang, , R. Nair

This study shows that Id proteins promote a cancer stem cell phenotype in triple negative breast cancer by negatively regulating Robo1, leading to Myc activation.

bioRxiv · Mar 11, 2020 · PreprintCancer Biology

Targeting the Id1-Kif11-Aurka axis in triple negative breast cancer using combination therapy

R. Murali, B. A. Varghese, N. Karthikeyan, A. P. T, W. S. Teo, A. McFarland, D. L. Roden, H. Holliday, C. Konrad, A. S. Cazet, E. Dodson, J. T. George, H. Levine, M. K. Jolly, A. Swarbrick, R. Nair

This paper investigates how Id1 and Id3 maintain chemoresistant CSCs in TNBC by targeting Kif11 and Aurka, and explores combination therapy to enhance tumor debulking.

bioRxiv · Sep 11, 2019 · PreprintCancer Biology